Jaap Verweij

Q: What Schools Are Affiliated With Jaap Verweij

Jaap Verweij is affiliated with the following schools: University of Auckland, Leiden University, Aarhus University, Institute of Cancer Research, Uppsala University

Jaap Verweij's AcademicInfluence.com Rankings

Jaap Verweij

Philosophy

#3403

World Rank

#5513

Historical Rank

Logic

#1137

World Rank

#1804

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jaap Verweij's Degrees

PhD Medical Oncology University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Jaap Verweij Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jaap Verweij's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (2009) (17488)
New Guidelines to Evaluate the Response to Treatment in Solid Tumors. (2000) (11951)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. (2000) (8707)
New guidelines to evaluate the response to treatment in solid tumors (2000) (3518)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial (2006) (2326)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. (2001) (1466)
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study (2001) (1307)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial (2004) (1269)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. (2006) (836)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. (2014) (808)
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). (2001) (706)
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. (2012) (632)
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). (2009) (611)
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. (2009) (591)
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. (2010) (590)
Soft tissue sarcomas of adults: state of the translational science. (2003) (559)
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (1999) (512)
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1995) (496)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. (2004) (449)
RECIST revisited: a review of validation studies on tumour assessment. (2006) (438)
Effects of St. John's wort on irinotecan metabolism. (2002) (429)
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. (1998) (425)
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. (2012) (414)
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. (2005) (413)
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. (1996) (406)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. (2002) (396)
Pharmacological Effects of Formulation Vehicles (2003) (395)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. (2005) (375)
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. (1997) (357)
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. (1999) (353)
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. (2000) (341)
Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. (1994) (337)
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. (2006) (332)
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. (2001) (324)
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. (2001) (320)
Precision oncology: an overview. (2013) (302)
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. (2005) (285)
Role of Formulation Vehicles in Taxane Pharmacology (2001) (282)
Irinotecan pathway genotype analysis to predict pharmacokinetics. (2003) (270)
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. (1998) (268)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. (2002) (267)
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. (1994) (260)
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype (2004) (253)
Clinical Pharmacokinetics of Docetaxel (2006) (242)
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (2007) (240)
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. (1994) (239)
Topoisomerase I inhibitors: topotecan and irenotecan. (1994) (236)
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. (2002) (234)
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. (2006) (230)
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. (1990) (230)
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of (2000) (226)
Mitomycin C: mechanism of action, usefulness and limitations. (1990) (225)
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours (2007) (223)
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients (2003) (220)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours (2003) (213)
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps (2005) (209)
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells (2013) (209)
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. (2008) (201)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom (2010) (194)
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial (2018) (192)
Complementary and alternative medicine during cancer treatment: beyond innocence. (2006) (190)
Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group (2005) (189)
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel (2005) (187)
Drug transporters of platinum-based anticancer agents and their clinical significance. (2011) (187)
Dosing strategies for anticancer drugs: the good, the bad and body-surface area. (2002) (182)
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. (1995) (182)
Individual patient data analysis to assess modifications to the RECIST criteria. (2009) (180)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era (2012) (180)
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. (2001) (178)
Alternative drug formulations of docetaxel: a review. (2007) (177)
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. (2003) (173)
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours (2010) (168)
Pharmacogenetic Pathway Analysis of Docetaxel Elimination (2009) (167)
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. (2002) (165)
Irinotecan‐induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein (2007) (162)
Mechanism-based pharmacokinetic model for paclitaxel. (2001) (161)
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. (2007) (157)
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. (1998) (157)
Effect of ABCG2 genotype on the oral vioavailability of topotecan (2005) (156)
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. (1996) (156)
Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics (2007) (155)
Drug Transporters and Imatinib Treatment: Implications for Clinical Practice (2010) (155)
Interaction of Cisplatin with the Human Organic Cation Transporter 2 (2008) (152)
ABCG2 Pharmacogenetics (2004) (151)
32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 (2008) (150)
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2000) (147)
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib (2006) (147)
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. (1997) (142)
Matrix metalloproteinase inhibitors: current developments and future perspectives. (2001) (140)
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. (1994) (138)
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. (1996) (136)
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. (1998) (136)
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. (2004) (135)
Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients (2004) (134)
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy (2001) (134)
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. (2014) (134)
Determining the optimal dose in the development of anticancer agents (2014) (134)
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1993) (133)
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. (2012) (131)
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. (2001) (131)
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck (1994) (131)
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. (2010) (130)
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? (2007) (130)
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. (2007) (128)
Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult (1994) (128)
Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. (1995) (127)
Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel (2004) (126)
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. (2001) (126)
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. (2002) (124)
Irinotecan (CPT-11) metabolism and disposition in cancer patients. (1998) (124)
Peripheral neurotoxicity induced by docetaxel (1996) (122)
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. (1993) (121)
Modulation of irinotecan metabolism by ketoconazole. (2002) (121)
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. (2005) (121)
Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure (2012) (120)
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. (1999) (120)
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. (2001) (120)
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea (2002) (117)
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. (1998) (115)
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (2002) (115)
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38 (2004) (114)
Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel (2004) (114)
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. (2002) (114)
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (112)
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Tr (2017) (110)
Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins (2003) (110)
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo (2014) (109)
Modulation of camptothecin analogs in the treatment of cancer: a review (2001) (109)
Role of pharmacogenetics in irinotecan therapy. (2006) (108)
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. (2004) (107)
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study (2009) (105)
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. (1991) (105)
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. (2005) (105)
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. (1999) (105)
Measurement of fraction unbound paclitaxel in human plasma. (2000) (104)
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients (2012) (104)
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. (2009) (103)
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. (1999) (103)
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours (2000) (101)
The potential of statins as part of anti-cancer treatment. (2005) (101)
Lessons learned from independent central review. (2009) (101)
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. (1990) (100)
Docetaxel administration schedule: from fever to tears? A review of randomised studies. (2005) (99)
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. (2009) (99)
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. (2000) (99)
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. (2005) (99)
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). (2006) (99)
Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). (1997) (98)
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. (2007) (98)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. (2003) (98)
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. (1998) (98)
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors (2013) (97)
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. (1998) (96)
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review (2005) (96)
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors (2004) (95)
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. (2002) (94)
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. (2002) (94)
Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia (2005) (92)
Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. (1990) (90)
Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors (2011) (90)
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. (1993) (90)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2014) (89)
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. (1999) (88)
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer (2002) (88)
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. (2006) (87)
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. (2000) (86)
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. (2002) (86)
CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity (2013) (86)
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. (2006) (86)
Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors (2005) (85)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 (2004) (85)
Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. (2005) (85)
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (84)
Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. (1998) (83)
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. (1999) (82)
Paclitaxel (Taxol) induces cumulative mild neurotoxicity. (1994) (81)
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. (1994) (81)
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. (1998) (81)
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours (2013) (81)
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane (2001) (81)
Development of Multidrug-Resistance Convertors: Sense or Nonsense? (2000) (81)
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. (1997) (80)
The applicability of mTOR inhibition in solid tumors. (2009) (80)
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro (1998) (80)
Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment (2008) (79)
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. (1994) (79)
ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition (2004) (78)
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. (2004) (78)
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. (1993) (78)
Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. (2012) (77)
A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. (1991) (76)
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. (1997) (74)
Renal toxicities of chemotherapy. (2006) (74)
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. (2010) (74)
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer (2002) (74)
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. (1997) (74)
Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients (2005) (73)
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. (2009) (73)
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. (2007) (73)
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. (1995) (72)
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. (2010) (72)
Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. (1995) (72)
Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors (2009) (72)
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. (1997) (72)
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells (2010) (71)
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. (2003) (71)
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. (1997) (71)
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. (1995) (71)
Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations (1996) (70)
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. (2000) (69)
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours (2007) (69)
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. (2003) (69)
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. (2000) (69)
Adjuvant therapy in primary GIST: state-of-the-art. (2012) (69)
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. (2012) (68)
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. (1996) (68)
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. (2000) (68)
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) (1997) (67)
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. (2007) (66)
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1999) (66)
Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients (2000) (66)
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. (1993) (65)
Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. (2003) (65)
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. (2004) (65)
A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan (2010) (64)
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. (1996) (64)
Prospective study on the dose relationship of mitomycin C–induced interstitial pneumonitis (1987) (64)
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. (1998) (63)
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. (2007) (63)
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. (1998) (63)
Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study (2011) (62)
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. (1998) (62)
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. (2002) (62)
Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP (1999) (62)
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway (2015) (62)
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients (2000) (61)
Cisplatin‐based chemotherapy in advanced adenoid cystic carcinoma of the head and neck (1992) (61)
CA 125 in ovarian cancer. (1992) (61)
MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR‐145 and miR‐451 as tumor suppressors (2014) (61)
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. (2004) (61)
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. (2005) (61)
Carcinoma of unknown primary: identification of a treatable subset? (1990) (61)
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. (2005) (61)
Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial (2006) (61)
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. (2000) (60)
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. (1996) (60)
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. (1993) (59)
Danusertib, an aurora kinase inhibitor (2012) (58)
Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 (2011) (58)
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles (2001) (57)
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. (2014) (56)
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. (2004) (56)
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors (2012) (56)
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. (2011) (56)
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. (2001) (55)
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. (2003) (55)
Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure (2009) (53)
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks (1995) (53)
Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. (2008) (53)
Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck (1996) (52)
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. (2008) (52)
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. (2002) (52)
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. (1994) (52)
The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. (1995) (51)
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. (1996) (50)
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. (1996) (50)
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? (2006) (50)
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. (1997) (49)
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. (2006) (48)
Population pharmacokinetics of cisplatin in adult cancer patients (2004) (48)
Imatinib and gastrointestinal stromal tumors: Where do we go from here? (2005) (48)
Dose-escalation models for combination phase I trials in oncology. (2010) (48)
Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. (2006) (48)
The use of oral cytotoxic and cytostatic drugs in cancer treatment. (2002) (48)
Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. (1987) (48)
Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure (2008) (47)
Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. (1991) (47)
Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. (2006) (47)
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours (1992) (47)
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors (2009) (47)
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (2007) (47)
Weekly high-dose cisplatin in malignant pleural mesothelioma. (1994) (46)
Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised pros (2007) (46)
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. (1995) (46)
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. (2002) (46)
Oral piritrexim, an effective treatment for metastatic urothelial cancer. (1993) (45)
EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials. (1991) (45)
A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). (1996) (45)
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. (1994) (45)
Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements (2008) (44)
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients (2007) (44)
Achievements and future of chemotherapy. (2000) (43)
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel (2006) (43)
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. (2000) (43)
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor (2011) (42)
Mechanism‐based models for topotecan‐induced neutropenia (2004) (42)
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38 (2002) (42)
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. (1996) (42)
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. (2002) (42)
Short report: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer (1991) (42)
Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development (2012) (42)
A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix (1999) (42)
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. (2010) (42)
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. (1998) (41)
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. (1994) (41)
Pazopanib, a new therapy for metastatic soft tissue sarcoma (2013) (41)
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. (1998) (41)
Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients (2012) (41)
Flat-Fixed Dosing of Irinotecan (2004) (41)
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. (2003) (41)
Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin (2009) (41)
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. (1994) (41)
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. (1999) (40)
Advances in Cancer Therapeutics (2009) (40)
Immunotherapy of metastatic renal cell cancer. (1996) (40)
Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies (2005) (40)
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. (2009) (39)
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure (1996) (39)
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. (1998) (39)
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. (2002) (39)
[Breast cancer in the early stage]. (2012) (39)
Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer (2011) (38)
11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1 (2009) (38)
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. (1993) (38)
Dispelling the myths around cancer care delivery: It's not all about costs (2014) (38)
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. (1995) (38)
Review of phase I clinical studies with topotecan. (1997) (38)
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. (2003) (38)
A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer (2004) (38)
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. (1995) (37)
Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. (2004) (37)
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. (2015) (37)
Renal Function as a Predictor of Irinotecan‐induced Neutropenia (2008) (36)
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. (2008) (36)
Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy (2012) (36)
Clinical Trial Design for Target Specific Anticancer Agents (2003) (36)
Factors affecting pharmacokinetic variability of oral topotecan: a population analysis (2004) (36)
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results? (1993) (35)
Lhermitte's sign following chemotherapy with docetaxel (1998) (35)
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1 (1997) (35)
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. (2006) (35)
STI571: a magic bullet? (2001) (35)
Effects of CYP Induction by Rifampicin on Tamoxifen Exposure (2012) (34)
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. (1995) (34)
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. (2004) (34)
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. (1993) (34)
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) (2000) (34)
Aurora kinase inhibitors. (2010) (33)
Cancer clinical trial outcomes: any progress in tumour-size assessment? (2009) (33)
The (ir)relevance of plasma protein binding of anticancer drugs. (2001) (33)
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors (2013) (33)
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. (2004) (33)
Soft tissue sarcoma trials: one size no longer fits all. (2009) (33)
Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. (1992) (32)
What is the role of dose‐dense therapy? (2005) (32)
Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography. (1999) (32)
Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group (2000) (32)
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies. (1998) (31)
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups. (1996) (31)
Experience with independent radiological review during a topotecan trial in ovarian cancer. (1997) (31)
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy? (2005) (31)
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. (2015) (30)
A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C (1988) (30)
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells (2001) (30)
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. (2005) (30)
Optimal control of acute cisplatin-induced emesis. (1996) (30)
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. (1999) (30)
5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. (1991) (29)
The epothilone dilemma. (2005) (29)
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. (1993) (29)
Antineoplastic Agents (1995) (29)
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. (2014) (29)
Rational Design of New TumoractivatedTM Cytotoxic Agents (1999) (29)
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. (2000) (28)
Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors (2005) (28)
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography. (1999) (28)
Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers (2000) (28)
A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. (2006) (27)
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel (2002) (27)
Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. (2007) (27)
Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. (1996) (27)
The use of protons in cancer therapy at PSI and related instrumentation (2006) (27)
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography. (2002) (27)
MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α (2014) (26)
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (26)
Medicinal cannabis in oncology. (2007) (26)
Metastatic Soft Tissue Sarcoma in Adults (2003) (26)
Gender-dependent pharmacokinetics of topotecan in adult patients (2000) (26)
Lifestyle habits as a contributor to anti-cancer treatment failure. (2008) (26)
Innovation in oncology clinical trial design. (2019) (26)
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography (2000) (26)
The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. (1999) (26)
Phase I drug combination trial design: walking the tightrope. (2009) (26)
Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. (1997) (26)
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. (1988) (26)
Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design. (2000) (25)
Paclitaxel pharmacokinetics, threshold models, and dosing strategies. (2003) (25)
The treatment of soft tissue sarcomas with focus on chemotherapy: a review. (1986) (25)
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. (1997) (25)
Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC (2008) (25)
Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. (1989) (25)
Limited sampling models for topotecan pharmacokinetics. (1994) (25)
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel. (2007) (24)
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. (1999) (24)
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors (2002) (24)
High-dose chemotherapy in adult sarcomas: no standard yet. (1999) (24)
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. (1994) (24)
The Price of Success: Cost‐Effectiveness of Molecularly Targeted Agents (2009) (23)
Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. (1996) (23)
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours (2010) (23)
Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. (2001) (23)
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules (2014) (23)
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel (1998) (23)
Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group. (1996) (23)
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis (2008) (23)
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. (2002) (23)
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe (2020) (23)
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. (2011) (23)
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. (2015) (23)
A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors (2004) (23)
Complete Remission of a Brain Metastasis to Third‐Line Hormonal Treatment with Megestrol Acetate (1990) (22)
Determination of fraction unbound docetaxel using microequilibrium dialysis. (2004) (22)
Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity (2007) (22)
Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future (1999) (22)
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature (2008) (22)
O6‐Methylguanine‐DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives (2002) (22)
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel. (1999) (22)
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group. (1996) (22)
Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer. (1991) (22)
An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. (2006) (22)
Hepatic transport, Metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain (2006) (22)
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. (1990) (22)
Multidisciplinary Treatment of Soft Tissue Sarcomas (1993) (22)
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group. (1997) (22)
Farnesyl transferase inhibitors: current developments and future perspectives. (2000) (22)
Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (21)
Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. (1999) (21)
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. (1997) (21)
Chemotherapy in the multidisciplinary approach to soft tissue sarcomas. EORTC Soft Tissue and Bone Sarcoma Group studies in perspective. (1992) (21)
Limited sampling model for area under the concentration time curve of total topotecan. (1996) (21)
蛍光検出逆相高速液体クロマトグラフィーによるヒト血しょう中イリノテカン(CPT‐11)とその活性代謝産物SN‐38の定量 (1997) (21)
Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design (2012) (21)
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. (1999) (21)
Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. (2000) (21)
A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform (2013) (21)
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. (2006) (20)
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. (2002) (20)
Adjuvant therapy in primary GIST: state-of-the-art. (2012) (20)
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. (1996) (20)
Other endpoints in screening studies for soft tissue sarcomas. (2008) (20)
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. (2000) (20)
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients (2008) (20)
A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck (1992) (20)
Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches (2003) (19)
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients (2004) (19)
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. (2000) (19)
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study (2013) (19)
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies (2010) (19)
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer (2001) (19)
Evaluation of patient enrollment in oncology phase I clinical trials. (2013) (19)
Gynaecological sarcomas (2007) (19)
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. (2009) (19)
Phase I studies of drug combinations. (2010) (19)
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study (2010) (19)
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. (2002) (18)
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. (2015) (18)
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin (2012) (18)
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. (2014) (18)
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. (1998) (18)
Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. (1995) (18)
Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. (1998) (18)
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. (1996) (18)
Medicinal cannabis in oncology practice: still a bridge too far? (2005) (18)
The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. (2014) (18)
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes (1996) (18)
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours (2004) (18)
Effect of Common CYP 3 A 4 and CYP 3 A 5 Variants on the Pharmacokinetics of the Cytochrome P 450 3 A Phenotyping ProbeMidazolam in Cancer Patients (2005) (18)
Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose. (2010) (18)
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. (1998) (18)
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer (1995) (17)
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer (2001) (17)
Capecitabine in breast cancer: current status. (2001) (17)
The EORTC and drug development (2002) (17)
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. (2004) (17)
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors (2006) (17)
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor (2004) (17)
The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. (2013) (17)
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours. (2002) (17)
Clinical pharmacokinetics of encapsulated oral 9‐aminocamptothecin in plasma and saliva (1999) (16)
Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. (1988) (16)
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2014) (16)
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours (2010) (16)
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. (1997) (16)
Abstract LB-201: Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors (2008) (16)
Severe side effects of the cytotoxic drug mitomycin-C. (1987) (16)
Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. (1991) (16)
Limited cerebrospinal fluid penetration of docetaxel (2004) (16)
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. (2011) (16)
A phase 1 study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. (2005) (16)
Practical aspects of managing gastrointestinal stromal tumors. (2006) (16)
Systemic treatment of advanced or metastatic soft tissue sarcomas. (1991) (15)
Multitarget tyrosine kinase inhibition: [and the winner is...]. (2007) (15)
New drugs for the treatment of sarcomas. (1995) (15)
Role of imatinib mesylate (Gleevec®/Glivec®) in gastrointestinal stromal tumors (2003) (15)
Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. (2005) (15)
A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin (2008) (14)
The relevance of microdialysis for clinical on:cology. (2006) (14)
Docetaxel (Taxotere): a new anti-cancer drug with promising potential? (1994) (14)
Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? (2006) (14)
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (14)
Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer (2004) (14)
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. (2003) (14)
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer (1997) (14)
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. (1996) (14)
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis (2003) (14)
Clinical cancer research 2001: new agents and therapies. (2001) (13)
Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group. (1994) (13)
Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule (1999) (13)
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer (2003) (13)
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. (2010) (13)
Modifying phase I methodology to facilitate enrolment of molecularly selected patients. (2013) (13)
Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group. (1996) (13)
Effect of valspodar on the pharmacokinetics of unbound paclitaxel (2003) (13)
Low Dose Methotrexate and Vinblastine, Given Weekly to Patients With Desmoid Tumours, is Associated With Major Toxicity (2003) (13)
Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment (1991) (13)
Toxic dermatitis induced by 10‐ethyl‐10‐deazaaminopterin (10‐EdAM), a novel antifolate (1990) (13)
13LBA Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study (2015) (13)
Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas? (2005) (13)
Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. (2006) (13)
Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study. (1994) (13)
Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor. (2000) (13)
Induction Chemotherapy with Cisplatin and Continuous Infusion 5‐Fluorouracil in Locally Far‐Advanced Head and Neck Cancer (1989) (12)
Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract. (1987) (12)
Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. (2010) (12)
The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. (1993) (12)
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase 1 study in patients with advanced solid malignancies (2006) (12)
Influence of ketoconazole on the fecal and urinary disposition of docetaxel (2007) (12)
Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study (2014) (12)
First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults. (2004) (12)
Clinical studies of camptothecin and derivatives. (2003) (11)
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands (2000) (11)
Phase II Study of Weekly Dose-intensified Cisplatin Chemotherapy with Oral Etoposide in Recurrent Glioma (1999) (11)
A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (ABT-510) in patients with advanced cancer (2002) (11)
Topoisomerase I inhibition: a new target or new missiles? (1995) (11)
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. (1998) (11)
The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. (1991) (11)
Topoisomerase I inhibitors and other new cytotoxic drugs. (1995) (11)
The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary (1996) (11)
Clinical Pharmacokinetics of 2′-Deoxy-2′-Methylidenecytidine (DMDC), a Deoxycytidine Analogue Antineoplastic Agent (2000) (10)
SPECIAL ARTICLE New Guidelines to Evaluate the Response to Treatment in Solid Tumors (2000) (10)
Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors (2008) (10)
The prognosis of prognostic factors in phase I clinical trials. (2000) (10)
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib (2008) (10)
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG) (2000) (10)
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG). (1993) (10)
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics (2019) (10)
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin. (2000) (10)
Relationship between clinical parameters and pharmacokinetics of mitomycin C (2004) (10)
'No risk, no fun': challenges for the oncology phase I clinical trial time-performance. (2008) (10)
New promising anticancer agents in development: what comes next? (1996) (10)
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin. (1999) (10)
565 Phase II studies with EO9 in breast, colorectal, gastric, pancreatic and NSCLC (1995) (10)
A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study (2000) (9)
Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients (1997) (9)
Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity (1997) (9)
Topotecan lacks third space sequestration. (2000) (9)
Distribution of paclitaxel in plasma and cerebrospinal fluid (2003) (9)
A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors (2005) (9)
Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. (2005) (9)
Adjuvant chemotherapy of soft tissue sarcomas. (1997) (9)
Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult (1993) (9)
Mechanisms of Action of Cancer Chemotherapeutic Agents: Antitumour Antibiotics (2005) (9)
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. (1993) (9)
Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies (2002) (9)
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine. (1993) (9)
Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site. (1993) (9)
Indium111 antimyosin for the detection of leiomyosarcoma and rhabdomyosarcoma (2004) (8)
Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma? (1997) (8)
Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy ± regional hyperthermia: EORTC 62961/ESHO-RHT 95 intergroup phase III study (2005) (8)
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group. (1994) (8)
The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. (1988) (8)
Etoposide for soft tissue sarcomas: fact or fiction. (1997) (8)
The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients. (2013) (8)
Clinical cancer research 2000: new agents and therapies. (2000) (8)
Effects of methimazole on the elimination of irinotecan (2010) (8)
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas (1995) (8)
Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC). (2016) (8)
"The Art of Successful Publication" ECCO 13 workshop report. (2006) (8)
Short report: Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma (1990) (8)
Etoposide and cisplatin in advanced esophageal cancer. A preliminary report. (1988) (8)
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: A South-East European Oncology Group study (2004) (8)
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation (2021) (8)
High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence? (1998) (8)
A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors (2005) (8)
Soft Tissue Sarcomas: Present Achievements and Future Prospects (1997) (8)
Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer. (1990) (7)
Population Pharmacokinetic Model for Cremophor EL (2005) (7)
Surrogate endpoints in advanced sarcoma trials: a meta-analysis (2018) (7)
A randomized phase I Bayesian dose escalation design for the combination of anti‐cancer drugs (2014) (7)
Piritrexim‐induced Pulmonary Toxicity (1993) (7)
Outcome of patients with PDGFRA D842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease. A study performed with the EORTC Soft Tissue and Bone Sarcoma Group (2010) (7)
KIT and PDGF as targets. (2004) (7)
CHAPTER 18 – CLINICAL TRIAL DESIGN: INCORPORATION OF PHARMACOKINETIC, PHARMACODYNAMIC, AND PHARMACOGENETIC PRINCIPLES (2002) (7)
RAPID ALKALINISATION FOR FLAVONE ACETIC ACID ADMINISTRATION: A POTENTIALLY HAZARDOUS PROCEDURE (1988) (7)
Determining the best dose for the individual patient. (2011) (7)
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group (2005) (6)
1LBA Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STS): Results of the randomized EORTC-ESHO intergroup trial (NCI-00003052) (2009) (6)
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer. (1999) (6)
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (6)
Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. (2002) (6)
Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. (2010) (6)
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma. (1996) (6)
Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
Mitomycin C-induced organ toxicity in Wistar rats: a study with special focus on the kidney (2004) (6)
The place of chemotherapy in the management of soft tissue sarcoma: experiences of the EORTC Soft Tissue and Bone Sarcoma Group. (1989) (6)
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices. (2004) (6)
[Severe tissue necrosis due to extravasation of mitomycin]. (1987) (5)
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. (1996) (5)
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study. (1998) (5)
Influence of medicinal cannabis (MC) on the pharmacokinetics (PK) of docetaxel (DOC) and irinotecan (CPT-11) (2005) (5)
A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies (2006) (5)
Health policy: Affordability of drugs used in oncology health care (2016) (5)
Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction (2012) (5)
Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST (2007) (5)
Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development. (1996) (5)
Acute blindness during treatment of recurrent or metastatic nasopharyngeal carcinoma with doxorubicin and CCNU. (1990) (5)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. (2004) (5)
27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors (2006) (5)
A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma. An EORTC Soft Tissue and Bone Sarcoma Group Study. (1989) (5)
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan. (2002) (5)
Phase I and pharmacokinetic study of Xeloda TM (capecitabine) in combination with docetaxel (1997) (5)
Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. (2006) (5)
Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. (1996) (5)
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group (2000) (5)
926 Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T), in a phase I study (1995) (5)
Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies (2008) (5)
Chemotherapy in advanced soft tissue sarcomas. (1989) (5)
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method (2006) (5)
Controlling cancer chemotherapy-induced emesis (1991) (4)
QTc prolongation and/or oncology drug development: who's in danger? (2008) (4)
Phase I and Pharmacokinetic Study of Brostallicin ( PNU-166196 ) , a New DNA Minor-Groove Binder , Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer 1 (2003) (4)
P3-115: Erlotinib (Tarcevar) “dosing–to–rash”: characterization of skin toxicity from a pilot phase II intra–patient dose–escalation study of E in previously treated patients with advanced non–small cell lung cancer (NSCLC) (2007) (4)
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study (1999) (4)
Targeted therapy: ready for prime time? (2004) (4)
The influence of functional polymorphisms in UGT1A7 and UGT1A9 on irinotecan pharmacokinetics in Asian cancer patients (2005) (4)
Phase II study with topotecan in colorectal cancer (1993) (4)
A phase II study of taxotere in patients with advanced head and neck cancer (1993) (4)
Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network (2003) (4)
Subtyping soft tissue sarcomas for treatment approaches (2012) (4)
694 EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma (2003) (4)
Clinical trials in drug development: a minimalistic approach (2012) (4)
Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance. (2004) (4)
Prevention of Acute Cisplatin-Induced Nausea and Vomiting (1996) (4)
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer (1992) (4)
Paclitaxel in patients (pts) with advanced angiosarcomas (2007) (4)
Frequent administration of Dabis Maleate, a phase I study. (1992) (4)
Treatment of Soft Tissue Sarcomas (2011) (4)
Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer (2004) (4)
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors (2002) (4)
Taxotere in advanced malignant melanoma: A fase-II trial of the eortc early clinical trials group (1993) (4)
Radioimmunodetection in rhabdo- and leiomyosarcoma with 111In-anti-myosin monoclonal antibody complex. (1990) (4)
Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear (1991) (4)
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. (1991) (4)
Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027 , Given on Days 1 and 8 of a 3-Week Cycle in Patientswith Advanced SolidTumors (2005) (4)
Controlling cancer chemotherapy-induced emesis. An update. (1991) (4)
The polyamine synthesis inhibitor SAM486A in combination with 5-FU/LV in metastatic colorectal cancer (MCC): results of a phase I and pharmacokinetic study (2000) (4)
Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study (2009) (4)
Phase I study on 4-weekly 6 hour infusion of BMY-25067 in patients (PTS) with solid tumors (1993) (3)
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. (1999) (3)
Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck. (1990) (3)
Primary care in cancer control: towards mature cancer care. (2015) (3)
CYP3A phenotype-based individualized dosing of irinotecan to reduce interindividual variability in pharmacokinetics and toxicity: Results from a randomized trial (2008) (3)
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. (2010) (3)
Effect of ABCG2 genotype and mRNA expression on the bioavailability of topotecan. (2004) (3)
Changing concepts in the systemic treatment of locally advanced or metastatic soft tissue sarcomas. (1993) (3)
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumors (1997) (3)
Molecular mechanisms of interethnic differences in irinotecan disposition: Impact of variants in ABCG2 (2005) (3)
Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin. (1990) (3)
The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy (2004) (3)
Sarcomas. (2020) (3)
Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer. (1987) (3)
Patient perception of the side effects of chemotherapy; the influence of the introduction of 5TH3 antagonists (1993) (3)
Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study. (2011) (3)
Emerging Drug Treatments for Solid Tumours (2012) (3)
Limited Potential of Hepatic Arterial Infusion of Irinotecan (2004) (3)
Targeting Treatment of Soft Tissue Sarcomas (2013) (3)
A Phase I study of taxotere (T) and gemzar (G) in patients with advanced solid tumors: impact of drug sequence and feasibility (1999) (3)
Phase II study on oral N-methylformamide in metastatic colorectal cancer. (1987) (3)
7th NCI-EORTC symposium on New Drugs in cancer therapy (2005) (3)
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. (2007) (2)
Phase I study of DABIS maleate given once every 3 weeks. (1991) (2)
Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma. (1990) (2)
Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. (1992) (2)
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis. (1999) (2)
GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design. (2008) (2)
Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors. (1989) (2)
Alveolar Soft Part Sarcoma: Should We Be Targeting the Tumor or Targeting the Vasculature? (2012) (2)
Phase I safety and pharmacokinetic (PK) study of sunitinib (S) in combination with ifosfamide (I) in patients (pts) with advanced solid tumors (STs). (2016) (2)
The multi-institutional phase I study: disadvantages without advantages? (2008) (2)
Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. (1992) (2)
Differential distribution and red blood cell partitioning of irinotecan and SN-38 in cancer patients (2002) (2)
Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs). (2012) (2)
Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer. (2004) (2)
Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients (2013) (2)
9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin (2009) (2)
Docetaxel and cisplatin in head and neck cancer. (2000) (2)
Principles of chemotherapy (2019) (2)
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics. (2003) (2)
The benefit of clinical benefit: a European perspective. (1996) (2)
Abstract A134: Pharmacokinetics and metabolism of iniparib for the treatment of metastatic triple-negative breast cancer (TNBC). (2011) (2)
Phase I study of weekly clsplatln (P) and weekly or four weekly taxol (T) in patients with advanced ovarian cancer (1997) (2)
Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM). (2011) (2)
Single-dimension CT measurements with RECIST 1.1 to evaluate liver metastases in GIST patients on imatinib (Abstract) (2012) (2)
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients. (1998) (2)
Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule. (1992) (2)
Phase I safety and pharmacokinetic (PK) study of SU014813 (S) in combination with docetaxel (D) in patients (pts) with solid tumors (STs) (2008) (2)
A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma (2004) (2)
Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance (2004) (2)
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer (2009) (2)
[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor]. (2003) (2)
72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors (2006) (2)
Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III study. (2011) (1)
Interaction of platinum compounds with the human organic cation transporter hOCT2 (SLC22A2) (2008) (1)
Highlights from the EORTC-NCI-AACR 2002 meeting: molecular targets and cancer therapeutics. (2003) (1)
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group. (1992) (1)
Early mortality rates: a tool for phase III trials or for changing standard practice? (2004) (1)
Predictive Biomarkers and Personalized Medicine CYP 3 A 4 22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity (2013) (1)
Abstract 1450: MicroRNAs in myxoid/round cell liposarcomas: FUS-CHOP regulated miR-497 and miR-30a target the insulin-like growth factor receptor pathway (2014) (1)
Effect of genetic variants in CYP2C8, CYP3A4, CYP3A5, and ABCB1 on paclitaxel pharmacokinetics (2005) (1)
Phase II study of a short course of weekly cisplatin (C) in locally advanced squamous cell carcinoma (SCC) of the head and neck (1993) (1)
Trial Methodology in Soft Tissue Sarcomas; the ‘One Plus One is Three or Zero’ Phenomenon (2008) (1)
Type of progression in patients treated with imatinib for advanced gastrointestinal stromal tumor (GIST): A study based on the EORTC-ISG-AGITG trial 62005. (2016) (1)
579 Phase I and Pharmacokinetic (PK) Study of Pazopanib in Combination with Two Schedules of Docetaxel (D) in Patients (pts) with Advanced Solid Tumors (2012) (1)
Mixed response to chemotherapy, a new entity in soft tissue sarcomas. (1995) (1)
A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer. (2009) (1)
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon. (2008) (1)
961 Phase I study of docetaxel and ifosfamide in patients with advanced solid tumors (1995) (1)
Prospective evaluation of the pharmacokinetic (PK) and toxicity profile of docetaxel in the elderly. (2004) (1)
344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors (2008) (1)
Is obtention of partial response (PR) in front line chemotherapy critical to improve outcome of metastatic soft tissue sarcoma (MSTS) patients (pts) (1998) (1)
403 Phase I study on RGB-286638, a novel, multi-targeted protein kinase inhibitor, administered as a 1-hour infusion on five consecutive days every 4 weeks in patients (pts) with recurrent or refractory solid tumors (2010) (1)
Cigarette smoking during irinotecan therapy: Effects on pharmacokinetics and neutropenia (2007) (1)
[Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents]. (2001) (1)
VEGF, sVEGFR-2, bFGF, and IL-8 as biomarkers of the pharmacological activity of BAY 57-9352, an oral VEGFR-2 receptor tyrosine kinase inhibitor, in patients with solid tumors. (2006) (1)
Phase II study with liposomal muramyl tripeptide phophatidylethanolamine (MTP/PE) in soft tissue sarcomas (STS) (1993) (1)
Neoadjuvant Chemotherapy Plus Regional Hyperthermia and Long-termOutcomes Among PatientsWith Localized High-Risk Soft Tissue Sarcoma The EORTC 62961-ESHO 95 Randomized Clinical Trial (2017) (1)
In reply [14] (2005) (1)
Clinical pharmacokinetics of liposomal lurtotecan (NX211) in whole blood, plasma and urine. (1999) (1)
Short report: Phase II study of ACNU as first-line treatment in advanced colorectal cancer (1991) (1)
[Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib]. (2003) (1)
Fifth NCI-EORTC symposium on new drugs in cancer therapy (2004) (1)
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag / Rij rats (1997) (1)
Pharmacokinetics and oral bioavailability of 9-amino-camptothecin PEG1000 capsules (1997) (1)
How to Define Treatment Success or Failure if Tumors Do Not Shrink (2008) (1)
Phase II study of mitoxantrone in locally advanced or metastatic adenoid cystic carcinomas (ACC) of the head and neck (1993) (1)
MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α (2014) (1)
Are 5HT3 antagonists fully cross-resistant? A pilot experience (1993) (1)
Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. (2011) (1)
7504 ORAL Early progression in patients with high-risk soft tissue sarcomas (STS): A phase III randomized prospective trial (EORTC/ESHO intergroup trial) of neoadjuvant chemotherapy with or without regional hyperthermia (RHT) (2007) (1)
[The Dutch Health Council report on palliative chemotherapy: possible confusion on ideas]. (2004) (1)
The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas (1994) (1)
Gastrointestinal Stromal Tumors (2006) (1)
565 Phase I combination study of oral vinorelbine (VRL) and oral cyclophosphamide (CTX) in patients with metastatic breast cancer (MBC) (2003) (0)
Phase I S tudy o f 3 -Week S chedule o f I rinotecan Combined W ith C isplatin i n P atients W ith A dvanced Solid T umors (2000) (0)
PIII‐75 (2006) (0)
Ethical considerations of St. John's wort interaction studies (2017) (0)
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients. (2008) (0)
Effects of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective open-label cross-over drug-interaction study. (2009) (0)
Contents, Supplement 1, 1996 (1996) (0)
Abstract 883: Imatinib-induced modulation of gastrointestinal and hepatic membrane transporters in mice. (2013) (0)
Perspectives of Subtyping in Soft Tissue Sarcomas: The Relevance for Clinical Trial Design (2012) (0)
7502 ORAL Assessment of plasma levels of soluble KIT (sKIT) as a potential surrogate marker for TTP in patients (pts) with advanced gastrointestinal stromal tumor (GIST) treated with sunitinib (2007) (0)
Metabolic disposition of irinotecan in plasma of patients receiving sequential treatment with cisplatin (1999) (0)
1256 POSTER Evaluation of Enrollment in Oncology Phase I Clinical Trials (2011) (0)
Abstracts of papers and posters Clinical Pharmacological Meeting (1993) (0)
Study of a NewNucleosideAnalogue , OSI-7836 , Using TwoAdministration Schedules in Patientswith Advanced SolidMalignancies (2006) (0)
Short communication A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma (1994) (0)
38 POSTER Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week off schedule in patients with advanced solid tumors (2006) (0)
Prophylactic treatment of irinotecan-induced diarrhea with neomycin (a randomized, placebo-controlled, double-blind study). (2006) (0)
Phase II study of a short course of weekly cisplatin (C) combined with oral etoposide (E) in pleural mesothelioma (1993) (0)
The multidisciplinary approach to treatment of soft tissue sarcomas. (1992) (0)
Principles and Examples of Cancer (Cell) Specific Therapies (2009) (0)
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway (2015) (0)
Oral ZD9331, a non-polyglutamated thymidylate synthase (TS) inhibitor: a phase I and pharmacologic study (1999) (0)
Abstract A189: Influence of smoking on the pharmacology of taxane therapy. (2011) (0)
The absence of influence of acetylsalicylic acid (ASA) on the transient decrease in platelet counts observed after infusion of bleomycin and vinblastine. (1985) (0)
A phase II study of high dose ifosfamide in metastatic colorectal cancer. (1989) (0)
A phase I study of the combination of daily oral sunitinib with intravenous ifosfamide in patients with advanced solid malignancies (2009) (0)
Adjuvant treatment of gastrointestinal stromal tumor: the proof, the pro, and the practice. (2012) (0)
Mitomycin C. (1988) (0)
Abstract ED02-02: Phasing out phase III trials: How much evidence do we need if the target is clearly hit? (2011) (0)
Pharmacokinetic, M etabolic, a nd P harmacodynamic Profiles i n a D ose-Escalating S tudy o f Irinotecan a nd C isplatin (2000) (0)
Body-Surface A rea-Based D osing D oes N ot I ncrease Accuracy o f P redicting C isplatin E xposure (2013) (0)
Phase I P harmacologic S tudy o f O ral T opotecan a nd Intravenous C isplatin: S equence-Depende nt H ematologic Side E ffects (2000) (0)
Mitomycin C (1987) (0)
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors (2007) (0)
Feasibility study of high dose ifosfamide (I) plus cisplatin (C) combined with rh-GCSF every 2 weeks in advanced solid tumors (1993) (0)
Impact o f B ody-Size M easures o n I rinotecan C learance: Alternative D osing R ecommendations (2002) (0)
Mitomycin C, prototype of a bioreductive alkylating agent (1991) (0)
Phase I and Pharmacology Studies (2004) (0)
Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. (2012) (0)
Target KIT and ETV1 in gastrointestinal stromal tumors (GIST) (2012) (0)
Mitomycin-C (1991) (0)
Radioimmunodetection and Radioimmunotherapy in Myosarcoma (1989) (0)
Phase I a nd P harmacokinetic S tudy o f t he O ral F arnesyl Transferase I nhibitor S CH 6 6336 G iven T wice D aily t o Patients W ith A dvanced S olid T umors (2001) (0)
Nursing care adaptations during clinical trials with weekly high‐dose cisplatin: evaluation of a process plan (1993) (0)
E¡ects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors (2002) (0)
Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? (2002) (0)
Capecitabine, a n O ral F luoropyrimidine C arbamate W ith Substantial A ctivity i n A dvanced C olorectal C ancer: Results o f a R andomized P hase I I S tudy (2000) (0)
Genetic predisposition to oral absorption of imatinib: Correlation of a variant allele in ABCG2 with transport activity (2005) (0)
Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics 1 (2003) (0)
Comparative P harmacokinetics o f U nbound P aclitaxel During 1 - a nd 3 -Hour I nfusions (2002) (0)
A phase II study of Gefitinib for patients with HER-1 expressing advanced synovial sarcoma refractory to doxorubicin-based chemotherapy. (2008) (0)
FREE PAPERS (Oral Presentations) (2007) (0)
Early response to neoadjuvant chemotherapy (NAC) in combination with regional hyperthermia (RHT) to predict long-term survival for adult-type high-risk soft tissue sarcoma (HR-STS): Results of the EORTC-ESHO intergroup phase III study. (2012) (0)
Phase I a nd P harmacologic S tudy o f O ral ( PEG-1000) 9-Aminocamptothecin i n A dult P atients W ith S olid T umors (1999) (0)
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. (2022) (0)
Phase I study on EO9 given every 3 weeks (1993) (0)
Clinical Management of Soft Tissue Sarcomas (2011) (0)
Primary care in cancer control (2015) (0)
Mitomycin C. (1990) (0)
Abstract A5: microRNA response to hypoxic stress in soft tissue sarcoma cells (2011) (0)
Confusion caused by similarity in manuscript titles. (2003) (0)
Abstract 4952: Functional characterization of microRNAs associated with the response to cisplatin of ovarian cancer cells (2011) (0)
394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours (2010) (0)
A phase I dose escalation study of BIBW 2992, an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER 2) in a 2 week on 2 week off schedule in patients with advanced solid tumors. (2005) (0)
First Clinical Experience with Cytorhodin S — The First Compound of a New Class of Anthracyclines (1989) (0)
Phase II study of Topotecan (TC) in patients (pts) with pretreated small-cell lung cancer (SCLC) (1994) (0)
Absence of interaction between furosemide and mitomycin C (2004) (0)
Cancer Therapy (1989) (0)
Phase I and pharmacoklnetic (PK) study of irinotecan (CPT-11) and cisplatin in patients with solid tumors: Preliminary results (1997) (0)
275 Taxanes in angiosarcomas (2009) (0)
EDATREXATE VERSUS METHOTREXATE IN HEAD AND NECK SCC 1651 (2019) (0)
654 Predictive value of a dextromethorphan phenotyping test for endoxifen exposure (2010) (0)
Phase II trials of drug combinations: fairytales or fact? (2005) (0)
A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy. (2018) (0)
Early Clinical Trials with Cytotoxic Agents (2011) (0)
Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level. (2012) (0)
Reply to F.L. Opdam et al (2012) (0)
Abstracts of papers clinical pharmacological meeting (2005) (0)
500PD NEW DIAGNOSTIC TECHNIQUES IN EARLY DIAGNOSIS OF MELANOMA IN SITU (2006) (0)
983 New drugs for the turn of the century (1995) (0)
Weekly high dose cisplatin (P) and daily oral vepesid (VP): A highly active salvage regimen for progressive or recurrent ovarian cancer after platinum therapy (1997) (0)
Evaluation of body‐surface area based dosing of cisplatin in patients with extreme BSA values (2005) (0)
The EORTC and drug development. European Organisation for Research and Treatment of Cancer. (2002) (0)
relationship ofcisplatin invitro: simulation of ani.v. bolus and3hand20hinfusion (1994) (0)
Pharmacokinetic-pharmacodynamic models for topotecan-induced neutropenia. (2004) (0)
Abstract 949: miR-634 restores drug sensitivity in tumor cells derived from patients with terminal drug-resistant ovarian cancer. (2013) (0)
Optimised Sample Preparation for Measurement of Cisplatin-DNA Adducts in White Blood Cells (1995) (0)
Influence of drug exposure and genetic variation on paclitaxel-induced neurotoxicity (2012) (0)
RAS-oncogene interacting agents (1999) (0)
An international multidisciplinary approach to the management of advanced colorectal cancer (First of two parts) (Reprinted from Eur J Surg Oncol, vol 23, Suppl A, August 1997) (1998) (0)
Introduction: Recent Topics in the Clinical Pharmacology of Taxanes that Might Change Future Perspectives (2001) (0)
Pharmaceutical industry, investigators and institutions: Partners or tools? (2005) (0)
Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM 486 A in Combination with 5-Fluorouracil / Leucovorin in Metastatic Colorectal Cancer (2004) (0)
Volume Contents (2004) (0)
Role of CYP3A4 phenotyping by midazolam clearance in predicting irinotecan pharmacokinetics. (2004) (0)
P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC. (2011) (0)
Taxanes in angiosarcomas (2009) (0)
P2-17-04: Induction of Tamoxifen Metabolism by Rifampicin: A Worrying Drug-Drug Interaction. (2011) (0)
PII‐20 (2006) (0)
Letter (2007) (0)
Docetaxel (taxotere) in adavanced malignant melanoma :a phase II study of the EORTC eraly clinical trials group (1994) (0)
Pharmacogenetic influence of OATP1B1 variants *1b and *15 on irinotecan disposition in Asian and Caucasian cancer patients. (2006) (0)
Trial design for cancer (cell)-specific anticancer therapies (2007) (0)
Biological and clinical aspects of drug-resistance and -sensitivity of malignancies (1998) (0)
382 Influence of rosuvastatin on the pharmacokinetics of imatinib: a cross-over study (2010) (0)
Effect of cigarette smoking on pharmacokinetics, safety and efficacy of imatinib: a study based on data of the Soft Tissue and Bone Sarcoma Group of the EORTC (2009) (0)
Short communication Determination of 5-fluorouracil in microvolumes of human plasma q by solvent extraction and high-performance liquid chromatography (1999) (0)
Possible lack of full cross-resistance between 5HT3 antagonists, a pilot experience (1993) (0)
Interactionof Cisplatinwith the HumanOrganic CationTransporter 2 (2008) (0)
What is the role of dose-dense therapy? (2005) (0)
[Vitamin A derivatives: potential prevention and therapy of solid tumors]. (1993) (0)
Limited potential of hepatic arterial infusion of irinotecan. (2004) (0)
[Microangiopathic hemolytic anemia and metastasized carcinoma]. (1986) (0)
Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study (1995) (0)
Phase II study of ACNU as first-line treatment in advanced colorectal cancer. (1991) (0)
Abstracts of Papers Presented at the Connective Tissue Oncology Society 4th Annual Scientific Meeting, 12–14 November 1998, Vancouver, BC, Canada (1999) (0)
Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. (2013) (0)
Randomized C ross-Over E valuation o f B ody-Surface Area-Based D osing V ersus F lat-Fixed D osing o f P aclitaxel (2003) (0)
Neo-adjuvant chemotherapy in adult soft tissue sarcoma. EORTC Protocol 62847 (1997) (0)
Effect of smoking on imatinib pharmacokinetics (2007) (0)
Epirubicin is not a substitute for Doxorubicine in advanced soft tissue sarcomas. Final data from the EORTC Soft Tissue and Bone Sarcoma Group (1998) (0)
New targets in oncology drug development. (2005) (0)
Predictive and mechanistic factors of tyrosine kinase inhibitor (TKI)-induced macrocytosis. (2010) (0)
The importance of quality and accuracy in the conduct of clinical trials: EORTC quality assurance measures (1992) (0)
Pharmacokinetic-pharmacodynamic models for topotecan-induced neutropenia (2004) (0)
Abstract ED01-01: Successes and failures of targeted drug development in adult and pediatric sarcomas (2019) (0)
7 Assessing target functionality for drug and patient tailoring: a clinical perspective (2010) (0)
Mechanism-Based P harmacokinetic M odel f or P aclitaxel (2001) (0)
Abstract CN04-02: Phase I trials: Limits and limitations in proof of concept (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jaap Verweij?

Jaap Verweij is affiliated with the following schools: